 Xiayuan Liang
Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2020 | 280 | 1.230 |
Why?
| | Receptor Protein-Tyrosine Kinases | 8 | 2013 | 221 | 0.810 |
Why?
| | Leukemia, B-Cell | 1 | 2020 | 13 | 0.690 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 4 | 2016 | 113 | 0.680 |
Why?
| | Gene Rearrangement | 3 | 2013 | 146 | 0.660 |
Why?
| | Biomarkers, Tumor | 4 | 2018 | 1185 | 0.630 |
Why?
| | Lymphoma, B-Cell | 1 | 2020 | 104 | 0.630 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 2 | 2013 | 20 | 0.620 |
Why?
| | Lymphoma, Extranodal NK-T-Cell | 1 | 2018 | 8 | 0.620 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2018 | 16 | 0.610 |
Why?
| | Leukemoid Reaction | 1 | 2016 | 3 | 0.550 |
Why?
| | GATA1 Transcription Factor | 1 | 2016 | 18 | 0.540 |
Why?
| | Genetic Association Studies | 1 | 2018 | 361 | 0.530 |
Why?
| | Point Mutation | 1 | 2016 | 224 | 0.510 |
Why?
| | Diseases in Twins | 1 | 2016 | 176 | 0.500 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2013 | 130 | 0.390 |
Why?
| | Hyaluronan Receptors | 2 | 2002 | 97 | 0.380 |
Why?
| | Down Syndrome | 1 | 2016 | 471 | 0.340 |
Why?
| | Lymphoproliferative Disorders | 2 | 2008 | 54 | 0.340 |
Why?
| | Glycoproteins | 2 | 2002 | 337 | 0.340 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2267 | 0.330 |
Why?
| | Proto-Oncogene Proteins | 5 | 2013 | 634 | 0.310 |
Why?
| | Killer Cells, Natural | 2 | 2008 | 426 | 0.270 |
Why?
| | Flow Cytometry | 5 | 2018 | 1142 | 0.270 |
Why?
| | In Situ Hybridization, Fluorescence | 4 | 2013 | 313 | 0.260 |
Why?
| | Leukemia | 1 | 2008 | 229 | 0.250 |
Why?
| | Chromosome Aberrations | 3 | 2018 | 148 | 0.250 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2007 | 92 | 0.250 |
Why?
| | Immunohistochemistry | 5 | 2013 | 1671 | 0.240 |
Why?
| | Hodgkin Disease | 1 | 2007 | 136 | 0.240 |
Why?
| | DNA Nucleotidylexotransferase | 1 | 2004 | 12 | 0.230 |
Why?
| | Skin Neoplasms | 2 | 2002 | 833 | 0.230 |
Why?
| | Proto-Oncogenes | 1 | 2004 | 29 | 0.230 |
Why?
| | Cytogenetic Analysis | 2 | 2020 | 34 | 0.230 |
Why?
| | Child | 14 | 2020 | 20805 | 0.220 |
Why?
| | Eye Neoplasms | 1 | 2003 | 16 | 0.220 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 1 | 2003 | 12 | 0.220 |
Why?
| | Stem Cells | 1 | 2008 | 579 | 0.220 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2004 | 430 | 0.210 |
Why?
| | Lymphomatoid Papulosis | 1 | 2002 | 1 | 0.200 |
Why?
| | Anaplasia | 1 | 2002 | 3 | 0.200 |
Why?
| | Child, Preschool | 9 | 2019 | 10450 | 0.180 |
Why?
| | Central Tolerance | 1 | 2021 | 10 | 0.180 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2021 | 36 | 0.180 |
Why?
| | Receptors, CXCR4 | 1 | 2021 | 82 | 0.180 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2013 | 75 | 0.170 |
Why?
| | Retrospective Studies | 7 | 2020 | 14571 | 0.170 |
Why?
| | Infant | 9 | 2019 | 8992 | 0.170 |
Why?
| | Male | 15 | 2021 | 63201 | 0.160 |
Why?
| | Liver Transplantation | 1 | 2007 | 799 | 0.160 |
Why?
| | Translocation, Genetic | 2 | 2013 | 98 | 0.160 |
Why?
| | Castleman Disease | 1 | 2019 | 12 | 0.160 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2019 | 28 | 0.160 |
Why?
| | Karyotyping | 1 | 2018 | 107 | 0.150 |
Why?
| | Histocytochemistry | 1 | 2018 | 81 | 0.150 |
Why?
| | Humans | 25 | 2021 | 129126 | 0.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 1573 | 0.150 |
Why?
| | Immunophenotyping | 3 | 2004 | 312 | 0.150 |
Why?
| | Herpesviridae Infections | 1 | 2019 | 134 | 0.140 |
Why?
| | Female | 15 | 2021 | 68517 | 0.140 |
Why?
| | Pregnancy, Triplet | 1 | 2016 | 4 | 0.140 |
Why?
| | Organic Cation Transport Proteins | 1 | 2016 | 26 | 0.130 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 325 | 0.130 |
Why?
| | Transcription Factors | 1 | 2004 | 1632 | 0.130 |
Why?
| | Prognosis | 4 | 2019 | 3788 | 0.130 |
Why?
| | Twins, Monozygotic | 1 | 2016 | 209 | 0.130 |
Why?
| | Biopsy | 1 | 2018 | 1086 | 0.120 |
Why?
| | RNA, Small Interfering | 3 | 2013 | 571 | 0.110 |
Why?
| | Trans-Activators | 1 | 2016 | 381 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2006 | 940 | 0.110 |
Why?
| | Databases, Factual | 1 | 2019 | 1279 | 0.110 |
Why?
| | c-Mer Tyrosine Kinase | 5 | 2013 | 44 | 0.100 |
Why?
| | Infant, Newborn | 3 | 2021 | 5739 | 0.100 |
Why?
| | Hypoproteinemia | 1 | 2012 | 5 | 0.100 |
Why?
| | Adolescent | 6 | 2019 | 20301 | 0.100 |
Why?
| | Blood Transfusion, Autologous | 1 | 2011 | 16 | 0.100 |
Why?
| | Incidence | 1 | 2018 | 2635 | 0.100 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2013 | 198 | 0.090 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2012 | 58 | 0.090 |
Why?
| | Edema | 1 | 2012 | 125 | 0.090 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 387 | 0.090 |
Why?
| | Leukemia, Myelomonocytic, Acute | 1 | 2009 | 7 | 0.080 |
Why?
| | Shock, Hemorrhagic | 1 | 2011 | 165 | 0.080 |
Why?
| | Apoptosis | 2 | 2010 | 2438 | 0.080 |
Why?
| | Anterior Chamber | 1 | 2009 | 20 | 0.080 |
Why?
| | Astrocytoma | 1 | 2010 | 121 | 0.080 |
Why?
| | DNA-Binding Proteins | 2 | 2008 | 1423 | 0.080 |
Why?
| | Acute Lung Injury | 1 | 2011 | 264 | 0.080 |
Why?
| | Eye Diseases | 1 | 2009 | 79 | 0.080 |
Why?
| | Colorado | 1 | 2018 | 4396 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2018 | 10226 | 0.070 |
Why?
| | Blood Platelets | 1 | 2011 | 375 | 0.070 |
Why?
| | Reed-Sternberg Cells | 1 | 2007 | 3 | 0.070 |
Why?
| | Adenoids | 1 | 2007 | 13 | 0.070 |
Why?
| | Palatine Tonsil | 1 | 2007 | 44 | 0.070 |
Why?
| | Bone Marrow Transplantation | 1 | 2008 | 268 | 0.070 |
Why?
| | Adult | 7 | 2019 | 35512 | 0.070 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2006 | 13 | 0.070 |
Why?
| | Drug Delivery Systems | 1 | 2009 | 326 | 0.060 |
Why?
| | Platelet Aggregation | 1 | 2006 | 91 | 0.060 |
Why?
| | Gene Knockdown Techniques | 3 | 2013 | 312 | 0.060 |
Why?
| | Organ Transplantation | 1 | 2008 | 219 | 0.060 |
Why?
| | Precancerous Conditions | 1 | 2007 | 161 | 0.060 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2010 | 750 | 0.060 |
Why?
| | Immunocompromised Host | 1 | 2007 | 195 | 0.060 |
Why?
| | Biliary Atresia | 1 | 2007 | 160 | 0.060 |
Why?
| | Phagocytosis | 1 | 2006 | 364 | 0.060 |
Why?
| | Wounds and Injuries | 1 | 2011 | 719 | 0.060 |
Why?
| | Lymph Nodes | 1 | 2007 | 467 | 0.060 |
Why?
| | Pregnancy | 1 | 2016 | 6375 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1021 | 0.050 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2004 | 71 | 0.050 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 963 | 0.050 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2003 | 16 | 0.050 |
Why?
| | RNA, Viral | 1 | 2007 | 617 | 0.050 |
Why?
| | Immunoenzyme Techniques | 1 | 2003 | 206 | 0.050 |
Why?
| | Ki-1 Antigen | 1 | 2002 | 5 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2003 | 211 | 0.050 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2004 | 125 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2021 | 2079 | 0.050 |
Why?
| | Gene Expression Regulation, Leukemic | 2 | 2013 | 50 | 0.050 |
Why?
| | Brain Neoplasms | 1 | 2010 | 1164 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2003 | 616 | 0.040 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2021 | 126 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2003 | 1209 | 0.040 |
Why?
| | Bone Marrow Cells | 1 | 2021 | 294 | 0.040 |
Why?
| | Survival Rate | 2 | 2019 | 1875 | 0.040 |
Why?
| | Bone Marrow | 1 | 2021 | 268 | 0.040 |
Why?
| | Macrophages | 1 | 2006 | 1466 | 0.040 |
Why?
| | Herpesvirus 8, Human | 1 | 2019 | 59 | 0.040 |
Why?
| | Immune Tolerance | 1 | 2021 | 349 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2013 | 813 | 0.040 |
Why?
| | Autoantigens | 1 | 2021 | 416 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2021 | 1230 | 0.040 |
Why?
| | Tumor Cells, Cultured | 2 | 2010 | 930 | 0.040 |
Why?
| | Organic Cation Transporter 2 | 1 | 2016 | 8 | 0.030 |
Why?
| | Mice | 4 | 2021 | 16644 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2002 | 1943 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2004 | 3033 | 0.030 |
Why?
| | Middle Aged | 3 | 2019 | 31079 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2021 | 823 | 0.030 |
Why?
| | Autoimmunity | 1 | 2021 | 860 | 0.030 |
Why?
| | Cell Lineage | 1 | 2016 | 334 | 0.030 |
Why?
| | Animals | 5 | 2021 | 34600 | 0.030 |
Why?
| | Disease Progression | 1 | 2002 | 2613 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2021 | 1901 | 0.030 |
Why?
| | Autoantibodies | 1 | 2021 | 1465 | 0.030 |
Why?
| | Aged | 2 | 2002 | 22089 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 3058 | 0.030 |
Why?
| | Risk Assessment | 1 | 2002 | 3260 | 0.020 |
Why?
| | Protein-Losing Enteropathies | 1 | 2012 | 10 | 0.020 |
Why?
| | Hypoalbuminemia | 1 | 2012 | 30 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1825 | 0.020 |
Why?
| | Platelet Activation | 1 | 2011 | 88 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2013 | 2060 | 0.020 |
Why?
| | Suppuration | 1 | 2009 | 9 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2010 | 168 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 4915 | 0.020 |
Why?
| | Cytarabine | 1 | 2009 | 56 | 0.020 |
Why?
| | Injections, Spinal | 1 | 2009 | 106 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2009 | 90 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-6 | 1 | 2008 | 8 | 0.020 |
Why?
| | Mice, SCID | 1 | 2009 | 347 | 0.020 |
Why?
| | Inflammation | 1 | 2019 | 2668 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 4838 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2009 | 584 | 0.020 |
Why?
| | Metalloproteases | 1 | 2006 | 43 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2011 | 2245 | 0.020 |
Why?
| | Solubility | 1 | 2006 | 229 | 0.020 |
Why?
| | Jurkat Cells | 1 | 2006 | 131 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2006 | 87 | 0.020 |
Why?
| | Cell Survival | 1 | 2009 | 1077 | 0.020 |
Why?
| | Thromboembolism | 1 | 2006 | 102 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 3184 | 0.020 |
Why?
| | Macrophage Activation | 1 | 2006 | 187 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2006 | 371 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2010 | 872 | 0.010 |
Why?
| | Rats | 1 | 2011 | 5173 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 5284 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2010 | 2347 | 0.010 |
Why?
| | Young Adult | 1 | 2019 | 12389 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2006 | 1353 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1403 | 0.010 |
Why?
| | Cohort Studies | 1 | 2008 | 5407 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2006 | 1924 | 0.010 |
Why?
|
|
Liang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|